Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

LifeMD, Inc. LFMD

Healthcare — Health Information Services

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
0.05
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — 1 — — — — — — — — —
Insider Ownership
18.03%

Capital & Financial Ratios

Market Cap
154.24
Revenue
191.59
Net Income
0.43
Free Cash Flow
(18.28)
Net Debt
(25.14)
Current Ratio
0.90
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
0.80
P/B ratio
19.32
Past 5Y EPS Growth
(10.98%)
This Y EPS Growth
(307.43%)
Next Y EPS Growth
82.37%
Next 5Y EPS Growth
(15.28%)
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 33.15 32.65 36.79 25.14
Receivables 5.28 10.46 9.31 11.26
Inventory 2.76 2.80 2.77 2.96
Other 1.42 3.04 2.97 2.73
42.60 52.37 51.83 42.08
2023 2024 2025 Q'26
Payables 11.08 10.90 14.15 18.16
ST’ Debt — 8.44 — —
Other — — — —
34.78 67.40 41.57 46.61
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡ ‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 50.16 47.28 — —
—
’25 50.89 49.02 60.17 33.98
194.06
’24 44.14 50.66 53.27 6.75
154.82
’23 33.13 35.95 38.61 44.86
152.55
’22 29.04 30.46 31.41 28.12
119.03
’21 18.20 22.31 24.95 27.42
92.88
’20 4.30 9.09 11.01 12.89
37.29
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 0.44 (6.93) — —
—
’25 3.07 8.64 (0.15) (3.28)
8.28
’24 5.20 4.54 6.70 1.07
17.51
’23 (2.61) 4.64 1.08 5.71
8.82
’22 (8.09) (10.10) (2.78) (1.97)
(22.94)
’21 (9.11) (10.73) (7.42) (5.83)
(33.09)
’20 0.66 (1.76) (4.50) (6.54)
(12.13)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (1.61) (8.56) — —
—
’25 1.06 5.80 (5.47) (2.64)
(1.24)
’24 3.01 1.41 3.20 1.68
9.31
’23 (4.43) 2.34 (1.33) 3.50
0.09
’22 (14.46) (12.61) (5.02) (3.74)
(35.83)
’21 (9.16) (11.66) (8.27) (7.40)
(36.49)
’20 0.59 (1.76) (4.83) (6.60)
(12.53)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.20) (0.16) — —
—
’25 0.01 (0.06) (0.10) 0.41
0.25
’24 (0.19) (0.19) (0.14) (0.02)
(0.53)
’23 (0.15) (0.23) (0.20) (0.12)
(0.70)
’22 (0.46) (0.45) (0.26) (0.40)
(1.57)
’21 (0.47) (0.64) (0.54) (0.62)
(2.29)
’20 (0.25) (0.30) (1.65) (2.56)
(4.44)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡ ‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 1.72 1.14 3.99 3.18 — — —
Low Price
‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 4.33 9.11 12.88 15.84 — — —
High Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 220 232 336 389 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.54 0.66 0.46 0.50 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 119.03 152.55 154.82 194.06 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 84.32% 87.61% 86.15% 85.72% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (44.66) (17.41) (22.58) (10.19) ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (37.52%) (11.41%) (14.58%) (5.25%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (45.02) (17.84) (20.86) 15.62 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 12.63 6.93 6.59 7.54 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.84 4.50 3.76 4.30 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.57) (0.70) (0.53) 0.25 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.74) 0.26 0.43 0.18 — — —
Cash Flow/Sh
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.42) (0.26) (0.20) (0.21) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.16) 0.00 0.23 (0.03) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.24) 0.16 (0.18) 0.51 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 30.98 33.91 41.20 45.13 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 13.12 ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.49 1.87 1.32 0.79 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ 0.00 51.35 0.00 6.65 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.49 1.78 1.22 0.68 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.64) 3,127.18 20.37 (106.73) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (22.94) 8.82 17.51 8.28 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
— — ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡ (12.89) (8.73) (8.21) (9.52) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (35.83) 0.09 9.31 (1.24) ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (20.06) 7.82 (15.03) 10.26 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.13 17.93 18.33 — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.17 (15.22) (14.32) (36.79) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (7.31) 5.57 (7.55) 23.16 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (128.70%) (56.34%) (36.43%) 15.35% ‡‡‡‡‡ — —
ROA
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% 0.00% 0.00% 0.00% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (988.99%) 751.79% 2,465.96% 144.18% ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

LifeMD (LFMD), a telehealth leader in primary care, men’s and women’s health, and weight management, has skyrocketed from $5.2 million in revenue in 2016 to $212 million in 2024, boasting a 70%+ CAGR fueled by the pandemic telehealth boom. Gross margins have climbed to an impressive 89%, operational efficiency is improving with revenue per employee steady at $600K+, and free cash flow flipped positive at $6 million last year—signs of a maturing business nearing profitability after years of losses.

Yet challenges linger: share dilution has swelled the count 6x, equity is negative, and recent insider selling totaling $4.7 million (with no buys) raises red flags amid a projected 2026 revenue dip. Trading at a dirt-cheap 0.96x price-to-sales—well below historical norms—LFMD offers analyst targets implying 116% to 440% upside, betting on weight-loss drug tailwinds like compounded semaglutide and a path to positive EPS by 2027.

This high-growth story echoes Teladoc and Hims’ rollercoasters, blending explosive potential with volatility and risks from competition and regulation. Dive into the full analysis for the numbers, projections, and why patient investors might find asymmetric opportunity here.

Read full commentary →

LifeMD, Inc. (LFMD) Latest News

News by impact score

Fine-tune

17 Sep

3 , 5:13 PM
AT&T launches Cricket 5G Home Internet service bundled with free virtual care access for subscribers. AT&T's virtual care offering creates new distribution channel for LifeMD telehealth services.

16 Sep

3 , 11:13 AM
AT&T partners with LifeMD to deliver virtual health care services, leveraging AT&T's infrastructure to broaden LifeMD's reach and potentially lift its shares. Partnership with AT&T adds distribution scale for LifeMD virtual care but impact remains limited to one channel expansion.

15 Sep

4 , 9:00 AM
AT&T launches free virtual healthcare access powered by LifeMD, becoming the first and only carrier to offer the service. Exclusive AT&T partnership delivers major expansion of LifeMD user base and market visibility.

23 Aug

3 , 1:09 AM
Analysts cut LifeMD (LFMD) fair value after lowering price targets on weaker guidance. Lowered targets on weaker guidance signal moderate near-term valuation pressure.

12 Aug

4 transcript www.fool.com, 8:13 PM
LifeMD (LFMD) held its Q2 2026 earnings call, covering financial results, operational updates, and forward guidance. Earnings call transcripts typically disclose results and outlook that directly move stock price and investor views.

6 Aug

4 transcript app.moby.co, 8:30 AM
LifeMD, Inc. held its Q2 2026 earnings call, presenting financial results, operational updates, and forward guidance for the telehealth company. Earnings call delivers core financial metrics and outlook that directly shape investor views and near-term stock movement.

5 Aug

4 , 7:45 PM
LifeMD, Inc. reported its second quarter 2026 financial results. Quarterly earnings releases deliver core financial data that directly shape stock valuation and investor outlook.

4 , 4:11 PM
LifeMD, Inc. reported its second quarter 2026 financial results. Quarterly earnings releases deliver key performance data that frequently drive major shifts in stock valuation and investor outlook.

3 transcript www.marketbeat.com, 11:03 PM
LifeMD Q2 earnings call highlights key financial results, revenue growth, subscriber metrics, and forward guidance on telehealth expansion and profitability targets. Q2 earnings details and guidance directly inform near-term financial trajectory and investor expectations without indicating major strategic shifts.

3 , 8:35 PM
LifeMD, Inc. (LFMD) posted a Q2 loss and missed revenue estimates. Q2 loss and revenue shortfall can pressure near-term stock price and sentiment without altering long-term trajectory.

3 Aug

3 transcript www.marketbeat.com, 8:03 PM
Medifast released Q2 earnings call highlights covering financial results, operational updates, and outlook in the weight management sector. Medifast earnings data offers competitive benchmarks that can moderately influence LifeMD positioning and investor views.

22 Jun

4 GlobeNewswire, 8:00 AM
LifeMD announces exclusive collaboration to launch direct-to-patient self-pay program for XYOSTED testosterone enanthate injection. Exclusive XYOSTED self-pay program launch expands LifeMD revenue channels in testosterone therapy.

18 May

4 Bloomberg, 4:23 PM
GLP-1 users are shifting to telehealth platforms to obtain weight loss drug prescriptions, increasing demand for services from providers including LifeMD. Rising telehealth adoption for GLP-1 drugs directly expands LifeMD addressable market and revenue in weight management.

7 May

4 app.moby.co, 8:30 AM
LifeMD, Inc. Q1 2026 earnings call summary details quarterly financial results, operational updates, and forward guidance for the telehealth provider. Quarterly earnings summaries drive significant shifts in investor sentiment and stock valuation through revealed financial metrics and outlook.

6 May

4 www.marketbeat.com, 10:16 PM
LifeMD reported Q1 revenue of $44.5 million, up 49% year-over-year, positive net income of $2.9 million, and Adjusted EBITDA of $4.6 million. Subscribers grew 33% to 323,000. Full-year 2024 guidance raised to $170-178 million revenue and $16-19 million Adjusted EBITDA. Q1 revenue beat, profitability achievement, and upward guidance revision indicate major positive shift in financial trajectory and investor confidence.

4 transcript www.fool.com, 6:16 PM
LifeMD (LFMD) released its Q1 2026 earnings call transcript detailing financial results, operational updates, and forward guidance. Q1 2026 earnings transcript discloses financial performance and strategic outlook capable of significantly impacting LFMD's stock trajectory.

4 GlobeNewswire, 4:05 PM
LifeMD, Inc. (LFMD) reported first quarter 2026 financial results. Quarterly earnings reports typically drive significant shifts in stock price and investor sentiment based on performance metrics.

3 Zacks, 6:30 PM
LifeMD, Inc. (LFMD) reported a first-quarter net loss while surpassing revenue estimates. Q1 loss despite revenue beat indicates moderately noticeable influence on financial performance.

2 May

4 Simply Wall St., 3:18 PM
LifeMD (LFMD) narrative shifts emphasis to GLP-1 drug growth and elevated 2026 expectations, signaling stronger future prospects amid telehealth expansion. GLP-1 growth focus and 2026 projections signal major strategic momentum for LFMD's revenue and market position.

21 Apr

3 www.marketbeat.com, 10:45 AM
Quest Diagnostics Q1 earnings call highlights partnerships and performance metrics involving LifeMD, Inc. (LFMD), noting growth in telehealth lab testing volumes. Quest Diagnostics' positive mentions of LifeMD partnership volumes moderately influence LFMD's operational visibility and investor sentiment.

3 , 8:00 AM
LifeMD (LFMD) stock surges 23.7%, prompting analysis on potential for further upside amid positive momentum. 23.7% stock surge reflects moderately noticeable boost to market sentiment and short-term performance trajectory.

17 Apr

4 Simply Wall St., 1:05 PM
LifeMD (LFMD) narrative shifts with aggressive GLP-1 growth plans targeting major market expansion and optimistic 2026 expectations amid telehealth competition. GLP-1 growth plans and 2026 outlook represent major strategic moves poised to significantly boost LFMD's market position and performance.

10 Apr

4 , 8:15 AM
LifeMD now offers Eli Lilly’s Foundayo™ (orforglipron), a new oral GLP-1 pill for weight management. Offering Lilly's innovative oral GLP-1 pill expands LifeMD's weight management portfolio in a high-demand market.

31 Mar

4 qz.com, 9:15 AM
Novo Nordisk launched a subscription program for Wegovy, its blockbuster weight loss drug, allowing patients direct access via a monthly fee covering medication and support services. Novo Nordisk's Wegovy subscription competes directly with LifeMD's telehealth GLP-1 offerings, potentially eroding market share and revenue.

4 GlobeNewswire, 8:45 AM
LifeMD launches industry-first telehealth subscription program for Novo Nordisk's Wegovy, enabling patients to access the weight-loss drug through virtual consultations, prescriptions, and home delivery for $299 per month, including ongoing clinical support. Offering Wegovy via telehealth subscription taps into booming GLP-1 demand, driving revenue growth and competitive edge in telehealth.

4 The Wall Street Journal, 8:33 AM
Novo Nordisk launched a discounted subscription program for its Wegovy obesity drug, offering doses starting at $299 per month without insurance requirements. Novo Nordisk's direct-to-consumer discounted Wegovy subscriptions intensify competition for LifeMD's telehealth weight loss services reliant on GLP-1 drugs.

4 PR Newswire, 7:46 AM
Novo Nordisk launches first and only multi-month subscription program for FDA-approved Wegovy®, offering savings of up to $1,200/year. Novo Nordisk's direct subscription for Wegovy with major savings competes directly with LifeMD's telehealth GLP-1 offerings, likely eroding its market share and growth.

20 Mar

4 Simply Wall St., 12:07 PM
LifeMD (LFMD) narrative shifts with accelerating GLP-1 growth and higher 2026 targets. GLP-1 expansion and raised 2026 targets represent major strategic growth drivers for LFMD.

16 Mar

4 , 8:00 AM
LifeMD, Inc. (LFMD) appointed a veteran healthcare finance executive as Chief Financial Officer and expanded its leadership team. Appointing a veteran CFO and expanding leadership bolsters financial strategy and investor confidence in a key operational area.

13 Mar

4 Simply Wall St., 2:15 AM
LifeMD (LFMD) returns to profitability and issues 2026 growth guidance, prompting a fresh valuation analysis. Profitability return combined with 2026 growth guidance represents major financial and strategic progress likely to enhance market performance and investor confidence.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us